Realtime | Geld | Brief | Zeit |
---|---|---|---|
1,460 | 1,560 | 25.07. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.06. | Barinthus Biotherapeutics plc. - 8-K, Current Report | 3 | SEC Filings | ||
09.06. | Barinthus Biotherapeutics plc: Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025 | 166 | ACCESS Newswire | OXFORD, GB AND GERMANTOWN, MD / ACCESS Newswire / June 9, 2025 / Barinthus Biotherapeutics plc announced that Bill Enright, CEO, will be presenting at the Investor Summit Virtual taking place on June... ► Artikel lesen | |
07.05. | Barinthus Biotherapeutics plc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
07.05. | Barinthus Biotherapeutics plc. - 8-K, Current Report | 1 | SEC Filings | ||
20.03. | Barinthus Biotherapeutics plc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
20.03. | Barinthus Biotherapeutics plc. - 10-K, Annual Report | 2 | SEC Filings | ||
20.03. | Barinthus Biotherapeutics Plc Full Year Loss Narrows | - | RTTNews | ||
20.03. | Barinthus Biotherapeutics plc. - 8-K, Current Report | 2 | SEC Filings | ||
BARINTHUS BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
20.03. | Barinthus Biotherapeutics: Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments | 860 | GlobeNewswire (Europe) | Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000)... ► Artikel lesen | |
06.03. | Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11 | 255 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th.About... ► Artikel lesen | |
10.01. | Barinthus Biotherapeutics: Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update | 437 | GlobeNewswire (Europe) | Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identifiedExtending... ► Artikel lesen | |
15.11.24 | Arbutus Biopharma Corporation: Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B | 408 | GlobeNewswire (Europe) | Significantly greater mean declines in HBsAg levels (p 23% of participants receiving imdusiran, VTP-300 and low-dose nivolumab reached HBsAg loss by Week 48 WARMINSTER, Pa. and OXFORD, United Kingdom... ► Artikel lesen | |
15.11.24 | Barinthus Biotherapeutics: Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion | 199 | GlobeNewswire (Europe) | Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC therapy seroconverted to HBsAb positivity. OXFORD, United... ► Artikel lesen | |
06.11.24 | Barinthus Biotherapeutics: Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results | 179 | GlobeNewswire (Europe) | OXFORD, United Kingdom, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that... ► Artikel lesen | |
01.10.24 | Barinthus Biotherapeutics: Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer | 144 | GlobeNewswire (Europe) | Investigational immunotherapy, VTP-300, is being evaluated as part of a potential functional cure regimen for chronic Hepatitis B.Interim data update for HBV003 anticipated in Q4 2024.Data update... ► Artikel lesen | |
24.09.24 | Barinthus Biotherapeutics: Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease | 375 | GlobeNewswire (Europe) | Investigational immunotherapy candidate, VTP-1000, seeks to address significant unmet need in people with celiac disease.An estimated one in 100 people globally suffer from celiac disease, for which... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 98,15 | 0,00 % | BioNTech SE: BioNTech veröffentlicht am 4. August 2025 Ergebnisse für das zweite Quartal 2025 und informiert über operativen Fortschritt | MAINZ, Deutschland, 21. Juli 2025(Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Montag, den 4. August 2025, die Ergebnisse für das zweite Quartal 2025 veröffentlichen. Darüber hinaus wird... ► Artikel lesen | |
MEDIGENE | 0,120 | -2,04 % | UNGLAUBLICHE Sondermeldung bei Medigene Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
QIAGEN | 43,870 | +0,52 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
CUREVAC | 4,612 | -0,43 % | Blueprint, Verona, CureVac & Co: Biotechs im Übernahme-Fieber - jetzt Comeback-Chance nutzen | Das Übernahmekarussell im Biotechnologie-Sektor kommt immer mehr in Fahrt. Zuletzt schnappte sich Merck & Co Verona Pharma. Bereits zuvor griff BioNTech bei CureVac zu. Und auch Sanofi zeigte sich auf... ► Artikel lesen | |
MODERNA | 29,130 | +0,19 % | 3 Charts in 3x33 Sekunden - Heute mit Moderna, Silber und RWE | Willkommen zu '3 Charts in 33 Sekunden'! Jörg Scherer stellt uns drei Charts vor, die er aktuell ganz besonders unter die Lupe nimmt. Welche Ziele oder Signale jetzt wichtig sind, erfahren Sie im Video!... ► Artikel lesen | |
AMGEN | 261,80 | +0,25 % | Amgen: Biotech-Riese nach Rücksetzer wieder im Fokus! | Spannende Pipeline im Adipositas-Segment! Rückblick Amgen ist ein führendes Unternehmen im Bereich der Biotechnologie. Es hat viel Erfahrung mit Medikamenten gegen Nierenerkrankungen und Krebs. Im Herbst... ► Artikel lesen | |
NOVAVAX | 6,325 | -0,49 % | Novavax, Inc.: Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study | Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose... ► Artikel lesen | |
BIOGEN | 111,70 | -0,27 % | Biogen's ZURZUVAE Wins EMA Panel Backing For Postpartum Depression Treatment | WESTON (dpa-AFX) - Biogen Inc. (BIIB), Friday announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has backed marketing authorization for ZURZUVAE... ► Artikel lesen | |
CRISPR THERAPEUTICS | 55,50 | 0,00 % | Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics | ||
PALATIN TECHNOLOGIES | 0,240 | 0,00 % | Palatin Technologies, Inc.: Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity | Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment
Combination of oral PL7737 and tirzepatide resulted in additive... ► Artikel lesen | |
REGENERON PHARMACEUTICALS | 482,70 | +0,58 % | $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today | ||
BIOXXMED | 0,410 | +32,26 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,280 | +1,59 % | INOVIO Pharma Announces Proposed Public Offering | WASHINGTON (dpa-AFX) - INOVIO Pharmaceuticals Inc. (INO) announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof)... ► Artikel lesen | |
OCUGEN | 0,942 | +0,94 % | Ocugen expands advisory board and leadership team for gene therapy push |